Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

Published:2011-05 Issue:9780 Volume:377 Page:1846-1854
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Herbst Roy S,Ansari Rafat,Bustin Frederique,Flynn Patrick,Hart Lowell,Otterson Gregory A,Vlahovic Gordana,Soh Chang-Heok,O'Connor Paula,Hainsworth John

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

3. Cancer management: a multidisciplinary approach;Pazdur,2004

4. Erlotinib (Tarceva) [package insert],2007

5. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

Cited by 353 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review;Frontiers in Oncology;2024-06-11

2. Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis;Cancers;2024-03-18

3. Nintedanib in Combination With Chemotherapy in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Cureus;2024-02-07

4. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors;Current Topics in Medicinal Chemistry;2023-12

5. Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations;Current Treatment Options in Oncology;2023-12